Issues related to prescription drug coverage and pharmacy benefits.
HR 5378, The Lower Costs More Transparency Act
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Issues related to prescription drug coverage, supply chain, and pharmacy benefits.
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Pharmacy contracting issues related to drug pricing and pharmacy networks.
HR 5378, The Lower Costs More Transparency Act
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Duration: January 1, 2011
to
present
General Issues: Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $2,830,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2011: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Behrends Foster Chief of Staff, Representative Dave Camp
Chief of Staff, Represetative Dave Camp
Chief of Staff, Represntative George (Buddy) Darden
Chris Long Legislative Assistant, Representative George (Buddy) Darden
Legislative Assistant, Rep. George (Buddy) Darden
Legislative Assistant, George (Buddy) Darden
Chris Huckleberry Chief of Staff, Representative Kurt Schrader
Chris Huckleberry [effective 1/9/24] Chief of Staff, Representative Kurt Schrader
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 22.
Original Filing: 301573117.xml
Lobbying Issues
Issues related to prescription drug coverage and pharmacy benefits.
HR 5378, The Lower Costs More Transparency Act
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug coverage, supply chain, and pharmacy benefits.
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy contracting issues related to drug pricing and pharmacy networks.
HR 5378, The Lower Costs More Transparency Act
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Dec. 29, 2023.
Original Filing: 301520991.xml
Lobbying Issues
Issues related to prescription drug coverage and pharmacy benefits.
HR 5378, The Lower Costs More Transparency Act
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug coverage, supply chain, and pharmacy benefits.
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy contracting issues related to drug pricing and pharmacy networks.
HR 5378, The Lower Costs More Transparency Act
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301512774.xml
Lobbying Issues
Issues related to prescription drug coverage and pharmacy benefits.
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug coverage, supply chain, and pharmacy benefits.
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy contracting issues related to drug pricing and pharmacy networks.
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 20, 2023.
Original Filing: 301490438.xml
Lobbying Issues
Issues related to prescription drug coverage and pharmacy benefits.
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug coverage, supply chain, and pharmacy benefits.
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy contracting issues related to drug pricing and pharmacy networks.
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs
S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare.
.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301467734.xml
Lobbying Issues
Issues related to prescription drug coverage and pharmacy benefits.
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to prescription drug coverage, supply chain, and pharmacy benefits.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy contracting issues related to drug pricing and pharmacy networks.
S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 14, 2023.
Original Filing: 301427673.xml
Lobbying Issues
Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Preferred Pharmacy Networks and Drug Rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 17, 2022.
Original Filing: 301405319.xml
Lobbying Issues
Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Preferred Pharmacy Networks and HHS Rebate Rule. S. Con. Res. 14 Budget Reconciliation. HR 5260 Reduced Cost and Continued Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation. S. Con. Res. 14 Budget Reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
Bluestone Strategies, LLC amended a lobbying report for representation of Pharmaceutical Care Management Association (PCMA) in Q22022 on Nov. 29, 2022.
Original Filing: 301423478.xml
Lobbying Issues
Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Preferred Pharmacy Networks and HHS Rebate Rule. S. Con. Res. 14 Budget Reconciliation. HR 5260 Reduced Cost and Continued Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation. S. Con. Res. 14 Budget Reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 15, 2022.
Original Filing: 301380896.xml
Lobbying Issues
Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Preferred Pharmacy Networks and HHS Rebate Rule. S. Con. Res. 14 Budget Reconciliation. HR 5260 Reduced Cost and Continued Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation. S. Con. Res. 14 Budget Reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 18, 2022.
Original Filing: 301359834.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Preferred Pharmacy Networks and HHS Rebate Rule. S. Con. Res. 14 Budget Reconciliation. HR 5260 Reduced Cost and Continued Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation. S. Con. Res. 14 Budget Reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301333200.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Essential Health Benefits; Preferred Pharmacy Networks and HHS Rebate Rule. HR 3684 Infrastructure Investment and Jobs Act. S. Con. Res. 14 Budget Reconciliation. HR 5260 Reduced Cost and Continued Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation. S. Con. Res. 14 Budget Reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 19, 2021.
Original Filing: 301306385.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Essential Health Benefits; Preferred Pharmacy Networks and HHS Rebate Rule. HR 3684 Infrastructure Investment and Jobs Act. S. Con. Res. 14 Budget Reconciliation. HR 5260 Reduced Cost and Continued Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation. S. Con. Res. 14 Budget Reconciliation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301286550.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Essential Health Benefits; Preferred Pharmacy Networks and HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301263757.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co- Payments; Essential Health Benefits; Preferred Pharmacy Networks and HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage and Direct Negotiation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234942.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Executive Order.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215309.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on July 17, 2020.
Original Filing: 301192386.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301177606.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128306.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Nov. 18, 2019.
Original Filing: 301091322.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 19, 2019.
Original Filing: 301052772.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks & HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage & Reform
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 25, 2019.
Original Filing: 301039671.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Preferred Pharmacy Networks and HHS Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 15, 2019.
Original Filing: 301005032.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 22, 2018.
Original Filing: 300996984.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Aug. 1, 2018.
Original Filing: 300980189.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 17, 2018.
Original Filing: 300946582.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 20, 2018.
Original Filing: 300931310.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300912382.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300895198.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on May 5, 2017.
Original Filing: 300879785.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending or Repealing P.L. 111-148; S. 637, C-Thru Act; HR 1939, Ensuring Seniors Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 23, 2017.
Original Filing: 300856289.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 18, 2016.
Original Filing: 300830810.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 20, 2016.
Original Filing: 300818339.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300800589.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 19, 2016.
Original Filing: 300776653.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; S. 1413, RX Abuse and Prevention; and S.1913, Pharmacy Lock-In
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 16, 2015.
Original Filing: 300754749.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues; HR 6, the 21st Century Cures Act; S. 1413, RX Abuse and Prevention; S.1913, Pharmacy Lock-In
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 17, 2015.
Original Filing: 300737873.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues and HR 6, the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 18, 2015.
Original Filing: 300720389.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 244, MAC Transparency Act; HR 793, Ensuring Access to Local Pharmacies Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and HR 804, Expanding the Availability of Medicare Data Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Specialty Drug Issues and 21st Century Cures legislation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700710.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 17, 2014.
Original Filing: 300679060.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 18, 2014.
Original Filing: 300662099.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on May 5, 2014.
Original Filing: 300651065.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
In Q4, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 18, 2014.
Original Filing: 300619930.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148) and Legislation Amending P.L. 111-148
Agencies Lobbied
U.S. Senate
Lobbying Issues
Federally-Funded Healthcare Programs; Medicare Advantage (MA)
Agencies Lobbied
U.S. Senate
4th Quarter, 2013
Bluestone Strategies, LLC amended a lobbying report for representation of Pharmaceutical Care Management Association (PCMA) in Q42013 on Jan. 18, 2014.
Original Filing: 300619995.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 18, 2013.
Original Filing: 300600380.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2013
In Q2, Bluestone Strategies, LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 19, 2013.
Original Filing: 300578204.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; Medical Loss Ratio and Preferred Pharmacy Networks.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2013
In Q1, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 18, 2013.
Original Filing: 300554667.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Legislation Amending P.L. 111-148; H.R. 1188, Preserving Our Hometown Independent Pharmacies Act; H.R. 1367, the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Genergic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ratio.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare, Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimbursement; Direct Negotiations; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act, Genergic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2012
In Q4, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 22, 2013.
Original Filing: 300537738.xml
Lobbying Issues
Implementation of the Patient and Affordable Care Act (P.L. 11-148); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ratio.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimburesement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2012
In Q3, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511844.xml
Lobbying Issues
Implementation of the Patient Protection and Affordability Act (P.L. 111-148): Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; H.R. 1971/S. 1058, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ratio.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimbursement; Direct Negotiations; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Reimportation; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2012
In Q2, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300492691.xml
Lobbying Issues
Implementation of the Patient Protection and Affordability Act (P.L. 111-149); Legislation Amending P.L. 111-148; H.R. 1946, Preserving Our Hometown Independent Pharmacies Act; S. 1058/H.R. 1971, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ration.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimbursement; Direct Negotiations; Medicare Drug Rebate; Medicare Part D Coverage; and Retiree Drug Subsidy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Reimportation; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2012
In Q1, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 19, 2012.
Original Filing: 300468677.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148); Legislation Amending P.L. 111-148; HR 1946, Preserving Our Hometown Independent Pharmacies Act; S. 1058/HR 1971, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure;Formulary Requirements;Generic Drug Co-Payments; Essential Health Benefits; and Medical Loss Ratio.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare;Medicaid;Pharmacy Payments; Average Manufacturer Pricing;Prescription Drug Remiburesement;Direct Negotiations;Medicare Drug Rebate;Medicare Part D Coverage Gap; and Retiree Drug Subsidy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Reimportation;Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2011
In Q4, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300450343.xml
Lobbying Issues
Implementation of the Patient Protection and Affordability Act (PL 111-148); Legislation Amending PL 111-148; HR 1946, Preserving Our Hometown Independent Pharmacies Act; S. 1058/HR 1971, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Payments; and Medical Loss Ratio.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimbursement; Direct Negotiations; Medicare Drug Rebate; Medicare Part D Coverage Gap; and Retiree Drug Subsidy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Reimportation; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues
Agencies Lobbied
U.S. Senate
3rd Quarter, 2011
In Q3, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300422485.xml
Lobbying Issues
Implementation of the Patient Protection and Affordability Act (PL 111-148); Legislation Amending PL 111-148; HR 1946, Preserving Our Hometown Independent Pharmacies Act; S 1058/HR 1971, Pharmacy Competition and Consumer Choice Act; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Pays; and Medical Loss Ratio.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Prescription Drug Reimbursement; Direct Negotiation; Medicare Drug Rebate; Medicare Part D Coverage Gap; and Retiree Drug Subsidy.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Reimportation; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2011
In Q2, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on July 19, 2011.
Original Filing: 300398363.xml
Lobbying Issues
Implementation of the Patient Protection and Affordability Act (PL 111-148); Legislation amending PL 111-148; Electronic Pricing; Chronic Care; PBM Disclosure; Formulary Requirements; Generic Drug Co-Pays; Medical Loss Ratio; HR 1946, Preserving Our Hometown Independent Pharmacies Act; S 1058/HR 5971, The Pharmacy Competition and Consumer Choice Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare; Medicaid; Pharmacy Payments; Average Manufacturer Pricing; Reimbursement; Direct Negotiations; Medicare Rebate; Medicare Part D Coverage Gap; Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act; Drug Reimportation; Generic Brand Settlement; Generic Dispensing; Generic Biologics; Speciality Drug Issues
Agencies Lobbied
U.S. Senate
1st Quarter, 2011
In Q1, Bluestone Strategies LLC lobbied for Pharmaceutical Care Management Association (PCMA) , earning $50,000. The report was filed on April 19, 2011.
Original Filing: 300373166.xml
Lobbying Issues
Implementation of and efforts to repeal or reform PL 111-148, the Patient Protection and Affordability Act, Competition in Healthcare Marketplace, Electronic Pricing, Chronic Care, PBM Disclosure, Formulary Requirements, Generic Drug Co-Payments, Medical Loss Ratio, Accountable Care Organizations
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare, Medicaid, Pharmacy Payments, Average Manufacturer Pricing, Reimbursement, Direct Negotiation, Medicare Rebate, Medicare Part D Coverage Gap, Retiree Drug Subsidy
Agencies Lobbied
U.S. Senate
Lobbying Issues
Pharmacy Act, Drug Importation, Generic Brand Settlement, Generic Dispensing, Generic Biologics, Speciality Drug Issues
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...